SCHEMBL7744035

SCHEMBL7744035

CCCc1c(OCCCOc2ccc(C(N)=O)c(OC)c2CCC)ccc2c1OC(C(=O)O)CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 20/20 1.00
LTB4R2 Q9NPC1 10/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8941423 0.95 LTB4R (0.90) LTB4RLTB4R2
SCHEMBL8941379 0.93 LTB4R (0.87) LTB4RLTB4R2
Sc-41390 SCHEMBL29369604 0.92 LTB4R (1.00) LTB4RLTB4R2
Sc-41390 SCHEMBL29403478 0.92 LTB4R (1.00) LTB4RLTB4R2
Sc-41390 SCHEMBL1889110 0.92 LTB4R (1.00) LTB4RLTB4R2
Sc-41390 SCHEMBL6372085 0.91 LTB4R (0.98) LTB4RLTB4R2
SCHEMBL9821850 0.90 LTB4R (0.82) LTB4RLTB4R2
SCHEMBL8941432 0.90 LTB4R (1.00) LTB4RLTB4R2
SCHEMBL5694768 0.89 LTB4R (0.95) LTB4RLTB4R2
SCHEMBL5694802 0.87 LTB4R (0.90) LTB4RLTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190216790-A1 Methods for Treating Pruritis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-07-18 US claimed
WO-2001034134-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO claimed
WO-2001034133-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO claimed
US-20190216790-A1 Methods for Treating Pruritis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-07-18 US disclosed
WO-2001034134-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO disclosed
WO-2001034199-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190216790-A1 Methods for Treating Pruritis ITCH, CYSLTR2, CYSLTR1 LTB4R 8/4885LTB4R2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.